Why Pfizer is Embedding Climate Science into Pharmaceuticals

Climate change poses mounting threats to global health infrastructure, pharmaceutical supply networks and the availability of critical medicines worldwide.

As extreme weather events intensify, natural resources become scarcer and emissions continue to rise, global biopharmaceutical companies face growing operational pressures alongside urgent societal obligations.

For Pfizer, sustainability has evolved from a corporate responsibility initiative into a strategic imperative that now shapes operations, capital allocation and research priorities.

The company recognises that addressing climate risks is essential not only for environmental stewardship but also for ensuring the resilience of healthcare systems globally.

Embedding climate science into corporate strategy

Pfizer's approach to climate action extends back more than two decades, with the company establishing its first formal GHG reduction target in 2001.

Between 2001 and 2020, the organisation achieved a reduction in GHG emissions exceeding 60%, demonstrating consistent progress across successive target periods.

The company's commitment to science-based climate action was formalised in 2015 when Pfizer became among the earliest corporations to secure validation from the Science Based Targets initiative.

This foundation enabled Pfizer to announce in 2022 its commitment to the voluntary Net-Zero Standard by 2040, a deadline that sits ten years ahead of the standard's requirements.

The approach aligns Pfizer's climate framework with guidance from the Intergovernmental Panel on Climate Change.

This alignment ensures that reduction targets are grounded in the latest climate science and contribute meaningfully to global efforts to limit temperature rise.

“We’ve strengthened our foundation, advanced our R&D pipeline and positioned our company for sustainable growth in the post-loss of exclusivity period," says Albert Bourla, CEO of Pfizer.

"We’re focused on serving patients with innovative medicines and vaccines while creating long-term value for our shareholders.” 

Decarbonising operations and value chains

The company has set targets to reduce direct and energy-related emissions by 46% by 2030, measured against a 2019 baseline, with ambitions to achieve a 95% reduction by 2040.

Central to this transformation is a commitment to source 100% of electricity from renewable sources by 2030.

However, Pfizer acknowledges that approximately 80% of its total GHG footprint originates within its broader value chain rather than from direct operations.

Consequently, addressing Scope 3 emissions has become a strategic priority.

The company aims to reduce value chain emissions by 90% by 2040, with intermediate targets concentrating on supplier engagement, logistics optimisation and business travel reduction.

By 2025, Pfizer expects 64% of its suppliers by emissions to have established science-based reduction targets of their own.

This collaborative approach recognises that meaningful decarbonisation requires systemic change across the entire pharmaceutical ecosystem.

Pfizer is working closely with suppliers to share best practices, provide technical support and incentivise emissions reductions throughout the supply chain.

Leveraging sustainable finance mechanisms

In 2020, Pfizer issued a US$1.25bn sustainability bond, marking the first issuance of its type within the biopharmaceutical industry.

The proceeds support initiatives designed to manage environmental impacts, reinforce healthcare infrastructure and broaden access to medicines and vaccines for underserved populations.

Sustainalytics assessed the bond framework as credible, impactful and aligned with leading international sustainability bond principles.

The company extended this approach in 2021 with a further US$1bn sustainability bond to support Covid-19 vaccine expenditure.

Beyond sustainable finance instruments, Pfizer has developed comprehensive climate risk assessments and business continuity programmes designed to protect manufacturing facilities and supply chains from escalating climate-related disruptions.

These assessments evaluate both physical risks, such as flooding and extreme heat and transition risks associated with policy changes and market shifts.

The integration of climate considerations into financial planning demonstrates how sustainability has become embedded within core business strategy rather than remaining a peripheral concern.

This approach enables Pfizer to allocate capital towards initiatives that deliver both environmental and business value.

Advancing sustainable product development

Pfizer is working to minimise the environmental footprint of its medicines throughout their entire lifecycle, from initial manufacturing through to final distribution.

This effort encompasses reducing GHG emissions, addressing water scarcity and discharge and eliminating substances of environmental concern.

The organisation is incorporating circular economy principles alongside green chemistry and biotechnology into its processes to enhance resource efficiency.

These innovations include designing molecules that degrade more readily in the environment and optimising manufacturing processes to reduce waste and energy consumption.

Through the development of sustainable medicines criteria, Pfizer seeks to demonstrate the social and environmental value embedded within its products whilst improving transparency and accountability.

This framework allows the company to measure and communicate the sustainability performance of individual medicines.

As climate change increasingly undermines global health outcomes, Pfizer is also prioritising expanded access to medicines and vaccines in communities facing disproportionate exposure to climate-related health risks.

This commitment recognises that climate justice and health equity are inseparable challenges requiring integrated solutions.